Anti-Cancer Drugs

Aims & Scope

Anti-Cancer Drugs reports both clinical and experimental results related to anti-cancer drugs, and welcomes contributions on anti-cancer drug design, drug delivery, pharmacology, hormonal and biological modalities and chemotherapy evaluation.

An internationally refereed journal devoted to the fast publication of innovative investigations on therapeutic agents against cancer, Anti-Cancer Drugs aims to stimulate and report research on both toxic and non-toxic anti-cancer agents.

Consequently, the scope on the journal will cover both conventional cytotoxic chemotherapy and hormonal or biological response modalities such as interleukins and immunotherapy.

Submitted articles undergo a preliminary review by the editor.

Some articles may be returned to authors without further consideration.

Those being considered for publication will undergo further assessment and peer-review by the editors and those invited to do so from a reviewer pool.

View Aims & Scope

---

Metrics & Ranking

Impact Factor

Year	Value
2025	2.2
2024	1.80

SJR (SCImago Journal Rank)

Year	Value
2024	0.532

Quartile

Year	Value
2024	Q3

Journal Rank

Year	Value
2024	10936

Journal Citation Indicator

Year	Value
2024	1094

---

---

Abstracting & Indexing

Journal is indexed in leading academic databases, ensuring global visibility and accessibility of our peer-reviewed research.

• Scopus
• Google Scholar
• Web of Science
• Medline
• Embase

---

Subjects & Keywords

Journal’s research areas, covering key disciplines and specialized sub-topics in Biochemistry, Genetics and Molecular Biology, Medicine and Pharmacology, Toxicology and Pharmaceutics, designed to support cutting-edge academic discovery.

---

Most Cited Articles

The Most Cited Articles section features the journal's most impactful research, based on citation counts. These articles have been referenced frequently by other researchers, indicating their significant contribution to their respective fields.

• Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators

  Citation: 626

  Authors: Tetsuhiko, Yuji, Hideyuki, Masahiro, Toshiyuki, Kazuhiko, Masakazu

• Drug-polymer conjugates

  Citation: 399

  Authors: Ruth

• Dendrimer-platinate

  Citation: 392

  Authors: Navid, Evagoras G, Ruth

• PI3K/Akt/mTOR pathway as a target for cancer therapy

  Citation: 370

  Authors: Daniel, Howard L.

• Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood–brain barrier

  Citation: 352

  Authors: Hans-Joachim, Manfred, Amina, Helga, Nadia, Volker

• A systematic review of the anticancer properties of berberine, a natural product from Chinese herbs

  Citation: 351

  Authors: Yiyi, Keli, Yitao, Xiuping

• Triterpenoids as new promising anticancer drugs

  Citation: 290

  Authors: Alessia, Gaetano, Ugo

• Liposomal encapsulated anti-cancer drugs

  Citation: 287

  Authors: Ralf-Dieter, Senta Ulrike, Ulrich, Andreas

• Antiproliferative effect of curcumin (diferuloylmethane) against human breast tumor cell lines

  Citation: 270

  Authors: Kapil, Panayotis, Theresa, Bharat B

• Histone deacetylase inhibitors in cancer treatment

  Citation: 251

  Authors: David M, R Charles

---